Description: EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, a Phase IIa clinical trial product candidate for the treatment of diabetic retinopathy; EG-Decorin, a Phase I/II clinical trial product for the treatment for pressure ulcers; EG-Myocin, a product that is in Phase II clinical trials for the treatment of heart muscle; and EG-HPV, a product that completed Phase I clinical trial for the treatment of cervical cancer. Its products in pipeline also include EG-TB for the treatment of tuberculosis; and EG-HZ, which is in preclinical trials for the treatment of herpes zoster. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Home Page: www.eyegene.co.kr
B-910, 401, Yangcheon-ro
Seoul,
07528
South Korea
Phone:
82 2 322 1687
Officers
| Name | Title |
|---|---|
| Mr. Won-Il Yoo | Chief Exec. Officer and Pres |
| Dr. Yang-Je Cho | Co-Founder and Chief Technology Officer |
| Soobeom Lee | Chief Financial Officer |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 66.0199 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 63 |